Takeda Pharmaceutical Co. Ltd.
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed February 13, 2025), Takeda Pharmaceutical Co. Ltd. reported 10 stock positions worth $38.0 million. Its top holding was Hillevax (HLVX) at 31.2% of the portfolio, followed by Wave Life Sciences (WVE, 29.1%) and Ovid Therapeutics (OVID, 23.4%). Compared with Q2 2024, it sold out of 3 and reduced 1. The biggest sale was an exit from Denali Therapeutics (DNLI).
- Most Recent 13F
- Q3 2025
- Location
- Tokyo, M0
- CIK
- 0001395064
- Portfolio Value
- $38.0M (Q3 2024)
- SEC Filing
- 0001395064-25-000030 ↗ filed Feb 13, 2025
Holdings Value
Holdings 10 stocks · $38.0M
| HLVX Hillevax Inc. | 31.18% | 6,724,000 | $11.8M | No change |
| WVE Wave Life Sciences Ltd. | 29.10% | 1,346,892 | $11.0M | No change |
| OVID Ovid Therapeutics Inc. | 23.42% | 7,531,996 | $8.9M | No change |
| STTK Shattuck Labs Inc. | 4.74% | 515,619 | $1.8M | No change |
| EQ Equillium Inc. | 3.99% | 1,824,977 | $1.5M | No change |
| XLO Xilio Therapeutics Inc. | 3.06% | 1,475,121 | $1.2M | No change |
| AMWL American Well Corp. Class A | 1.94% | 77,733 | $737K | No change |
| TSBX Turnstone Biologics Corp. | 1.31% | 895,824 | $499K | No change |
| RANI Rani Therapeutics Holdings Class A | 1.16% | 203,190 | $439K | Reduce -5.6% |
| LAB Standard Biotools Inc. | 0.08% | 16,515 | $32K | No change |
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 8 | $16.4M | OVID, EQ, XLO, STTK, LYEL |
| Q2 2025 | 11 | $19.6M | HLVX, OVID, XLO, AMWL, EQ |
| Q1 2025 | 11 | $16.2M | HLVX, OVID, XLO, EQ, AMWL |
| Q4 2024 | 11 | $26.6M | HLVX, OVID, XLO, EQ, STTK |
| Q3 2024 | 10 | $38.0M | HLVX, WVE, OVID, STTK, EQ |
| Q2 2024 | 13 | $232.3M | DNLI, HLVX, PHAT, WVE, OVID |
| Q1 2024 | 15 | $289.0M | HLVX, DNLI, PHAT, OVID, STTK |